Finnish biotechnology company FIT Biotech Oy will together with Icosagen AS develop a new Ebola vaccine.
The product development work is based on patented technologies allowing induction of passive and active immunotherapy, states FIT Biotech. The parties will also collaborate with international partners from France and Switzerland. The clinical stage is exepected to start at the latest in 2016.
“We are pleased to be able to apply our vaccine technology in developing an Ebola-vaccine. Our strategy is to exploit the potential of our technology to develop new gene therapies. We also feel that taking active role in this case is part of our societal responsability,” said Kalevi Reijonen, CEO at FIT Biotech.